
CAS 2007975-22-4
:Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
4 produits concernés.
3-Methyl-7-(tetrahydro-2H-pyran-4-yl)-2-((trans-4-(trifluoromethyl)cyclohexyl)methoxy)imidazo[5,1-f][1,2,4]triazin-4(3H)-one
CAS :Formule :C19H25F3N4O3Degré de pureté :98%Masse moléculaire :414.4223-Methyl-7-(Tetrahydro-2H-Pyran-4-Yl)-2-((Trans-4-(Trifluoromethyl)Cyclohexyl)Methoxy)Imidazo[5,1-F][1,2,4]Triazin-4(3H)-One
CAS :3-Methyl-7-(Tetrahydro-2H-Pyran-4-Yl)-2-((Trans-4-(Trifluoromethyl)Cyclohexyl)Methoxy)Imidazo[5,1-F][1,2,4]Triazin-4(3H)-OneDegré de pureté :98%Masse moléculaire :414.42g/molDSR-141562
CAS :<p>DSR-141562 is a potent and selective inhibitor of phosphodiesterases. The compound was shown to inhibit the activity of PDE4 selectively, with little or no inhibition of other phosphodiesterases. DSR-141562 has been shown to be effective in animal models for depression and hyperactivity. The drug also has a profile that suggests it may have therapeutic potential for the treatment of neurodevelopmental disorders, including autism spectrum disorder. This drug has been shown to be orally active in animal models and is expressed in tissues such as brain, liver, kidney, heart, lung, and spleen. DSR-141562 inhibits the activity of dopamine transporter (DAT) and norepinephrine transporter (NET), which are proteins that are responsible for removing dopamine from synapses in the brain.</p>Formule :C19H25F3N4O3Degré de pureté :Min. 95%Masse moléculaire :414.4 g/molDSR-141562
CAS :<p>DSR-141562 is a new compound that can be taken orally and has a specific ability to inhibit phosphodiesterase 1 (PDE1) in the brain. This compound exhibits a preference for inhibiting human PDE1B, with an IC50 value of 43.9 nM. It also shows moderate inhibition of human PDE1A (IC50 = 97.6 nM) and PDE1C (IC50 = 431.8 nM). DSR-141562 is particularly useful in the study of positive symptoms, negative symptoms, and cognitive impairments associated with schizophrenia.</p>Formule :C19H25F3N4O3Couleur et forme :SolidMasse moléculaire :414.42




